Citi analyst Joanne Wuensch raised the firm’s price target on Boston Scientific (BSX) to $125 from $119 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strategic Growth and Financial Resilience Underpin Buy Rating
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
- Boston Scientific reinstated with a Buy at Erste Group
- Boston Scientific’s Growth Potential Bolstered by AGENT DCB Expansion and Reimbursement Developments
- Boston Scientific Stockholders Approve Key Governance Proposals